Patent issue. Currently known to causes apoptotic cell death, cellular proliferation, differentiation, inflammation, and viral replication promoting.

Slides:



Advertisements
Similar presentations
RHEUMATOID ARTHRITIS MUHAMMAD ADEEL (BIOT 412) Human Diseases Presentation.
Advertisements

Innate Immunity (part II) and Antigen Recognition by Adaptive Immunity
Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:
Cytokines receptors and biological functions. Cytokine Receptors  These are the receptors present on membrane of responsive target cells by which cytokines.
Understanding the Immune System
Biologic therapy Spyridon Gkalpakiotis,MD,PhD Dermatovenereology department Third faculty of medicine,Charles University,Prague.
Biologics in psoriasis (2008) Dr. Amal Kokandi. What are biologics?  "biologics" are made from human or animal proteins. Biologics have been in use for.
Scott Vogelgesang, MD Division of Immunology, Rheumatology and Allergy University of Iowa BIOLOGIC AGENTS: CURRENT AND FUTURE No conflicts of interest.
By Claire Baldock © Boult Wade Tennant 2011 Therapeutic Antibodies – Technical Introduction AIPPI Forum Hyderabad Pharma Workshop.
MONOCLONAL ANTIBODIES
Cause of disability. Changes in the joint inflammation, proliferation of the synovium, errosion of cartilage & bones.
R HEUMATOID A RTHRITIS BMJ 2011;342: RA is a systemic inflammatory autoimmune disease with localised and general manifestations. It is characterised.
North American Neuromodulation Society Meeting 2012 Harnessing the Inflammatory Reflex: Using Neuromodulation as a Novel Approach to Treat Chronic Inflammatory.
Abrar M. Radwan Saleh Dr. Adham Abo-Taha An-Najah National University College of Pharmacy Pharmacy Program: Pharm D.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.
Tumor Necrosis Factor Inhibitors Box Warnings
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
Adaptive Immunity: Specific Defenses of the host
Drug Development - clinical trials phase I: healthy volunteers [safety evaluation] phase II: diseased individuals [safety and efficacy] phase.
Immunity [Innate and Acquired Immunity]. Biotechnology RED: Medical Area GREEN: Agriculture/Food Science WHITE: Bioprocess Engineering.
Lectures 12 Cytokines and Immune Response September 24, 2004 Chris Schindler Reading: Janeway - as indicated Abbas - Chapter 11.
Immunology Unit Department of Pathology College of Medicine King Saud University.
TNF a inhibitors BY: MOHAMMED ALSAIDAN. Biologics Biologic agents are proteins that can be extracted from animal tissue or produced by recombinant DNA.
The Biochemistry of Rheumatoid Arthritis Cindy Zhang Yalda Pour Shahnazari Jessica Marcantonio Victoria Wong PHM142 Fall 2015 Coordinator: Dr. Jeffrey.
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Lecture 6 clinical immunology Cytokines
Disease modified Anti-rheumatic drugs ( DMARD)
ARTHRITIS Rheumatoid Arthritis Presented By: Ali Raza Ansar Qudsia Sehar Hafsa Kabir Rheumatoid Arthritis Presented By: Ali Raza Ansar Qudsia Sehar Hafsa.
Multiple anti-TNFα drugs motives and implications Presented by: Ofer Katzir, Yonatan moshkovits and Asher Moshe June 2015.
Unit 12: Immune System Disorders. Allergies: An inaccurate immune system response to something usually harmless like pollen, fur, a particular food, or.
Advances in the Treatment of Crohn’s Disease GASTROENTEROLOGY 2004;126:1574–1581.
Group D.N.A. Members  Bae.J.H.  Jeong.J.H.  Lee.S.B.  Liujiahzau  Oh.E.T Group D.N.A. Members  Bae.J.H.  Jeong.J.H.  Lee.S.B.  Liujiahzau  Oh.E.T.
Immunotherapy. Definition The approach to balance or intervene the immunologic function in order to fight against the disease by the principle of immunology.
Disease Modifying Antirheumatic drugs. At the end of the lecture the students should: Know the pathogenesis of rheumatoid joint damage Emphasize the rational.
Page 1 What is TNFWhat is TNF? --Creative BioMart.
Adalimumab Drugbank ID : DB00051
I am in the Biotechnology industry
Brodalumab Drugbank ID : DB11776 Molecular Weight (Daltons) :144,000
Difference to Generics What can they do for us in the future
B-cell mediated disease
ID DB06372 RILONACEPT CATEGORY Immunosuppressive Agents.
Immune Keytruda.
Mechanisms of T Cell Tolerance
Cytokines: Introduction
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
Chapter 18 Immunological Disorders
Drugbank ID : DB00005 Half life : 102 +/- 30 hrs
Adalimumab 40mg Exemptia Injection
IMMUNOGLOBULIN STRUCTURE AND FUNCTION
Epidemiology of rheumatoid arthritis
Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline to Witness Many Collaborations in Coming Years.
Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.
Therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a.
Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.
Human antibody discovery Based on the technology of B cell sorting, Creative Biolabs provides Native™ human antibody discovery service to generate native.
Psoriasis What’s New Dr. Vincent P Beltrani
Other Cells of Immune System
Figure 3 Strategies to achieve therapeutic inhibition of IL-1
BIOLOGICS.
Figure 3 Effect of sialylated glycoforms on IgG activity
Epidemiology of rheumatoid arthritis
Nat. Rev. Rheumatol. doi: /nrrheum
Disease Modifying Anti-rheumatic drugs
Department of Pathology
SLE: the many players involved in systemic autoimmunity and tissue destruction. SLE: the many players involved in systemic autoimmunity and tissue destruction.
Overexpression of IL-12, IL-23 or their receptors is implicated
Fusion protein expression Profacgen. Fusion proteins are widely used to investigate protein functions, and to facilitate protein expression and purification,
Women With Psoriasis Are Struggling More Than Men
Presentation transcript:

Patent issue

Currently known to causes apoptotic cell death, cellular proliferation, differentiation, inflammation, and viral replication promoting various aspects of immunity and inflammation High level of TNF-α induces the inflammatory response, which in turn causes many of the clinical problems associated with autoimmune disorders such as rheumatoid arthritis Reduction in the level of TNF-α  new therapeutics to treat autoimmune disease like rheumatoid arthritis Discovery of a new aspect of TNF-α-related signaling

Neutralizing the biological effects of TNF-α in situations where over-expression of TNF-α causes negative clinical effects Soluble forms of TNF receptor : trapping TNF-α in blood  Reduce the severity of many diseases caused by high level of TNF-α Enbrel : TNF-α blocker approved for medical use - Developed by Immunex and approved by FDA in Amgen acquired Immunex in Engineered hybrid protein consisting of the extracellular domain of the TNF-α-R75 fused directly to the Fc region of human IgG - Dimeric soluble protein TNF-Receptor Fc

Most widely used for treatment of disorders caused by excess TNF-α - Rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. - Administered as a twice weekly via subcutaneous injection (25 in WFI) - Annual sale : $ 4.5 billion in 2010 Competitors : Humira, Remicade (Monoclonal Ab) Development of new version with greater potency - Protein engineering : structure-based rational design - Increased affinity /specificity - Stability in blood